Validation of a fast and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) with atmospheric pressure chemical ionization method for simultaneous quantitation of voriconazole, itraconazole and its active metabolite hydroxyitraconazole in human plasma

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 2, 2013, Pages 339-346

  Xiong, Xin ^a,b   Zhai, Suodi ^a   Duan, Jingli ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

human plasma; hydroxyitraconazole; itraconazole; LC APCI MS MS; voriconazole

Indexed keywords

ACETONITRILE; AMMONIUM FORMATE; DRUG METABOLITE; HYDROXYITRACONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ARTICLE; BLOOD SAMPLING; CORRELATION COEFFICIENT; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SELECTIVITY; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; DRUG MONITORING; HUMANS; ITRACONAZOLE; LIQUID-LIQUID EXTRACTION; PYRIMIDINES; TANDEM MASS SPECTROMETRY; TRIAZOLES;

EID: 84875445058     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0364     Document Type: Article

References (34)

1. Cuenca-Estrella M, Bernal-Martinez L, Buitrago MJ, Castelli MV, Gomez-Lopez A, Zaragoza O, et al. Update on the epidemiology and diagnosis of invasive fungal infection. Int J Antimicrob Agents 2008;32(Suppl 2):S143-7.
2. Kofla G, Ruhnke M. Voriconazole: review of a broad spectrum triazole antifungal agent. Expert Opin Pharmacol 2005;6: 1215-29.
3. Sharkey PK, Rinaldi MG, Dunn JF, Hardin TC, Fetchick RJ, Graybill JR. High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991;35:707-13.
4. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:1570-2.
5. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single-or multipledose administration. Antimicrob Agents Chemother 2004;48:2166-72.
6. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003;31:540-7.
7. Keith T, Nigel B, Konrad T, Peter T, Nolan W. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006;46:235-43.
8. Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007;67: 269-98.
9. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998;35:461-73.
10. Haria M, Bryson HM, Goa KL. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 1996;51:585-20.
11. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008;21: 580-6.
12. Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009;89:592-9.
13. Alffenaar JW, de Vos T, Uges DR, Daenen SM. High voriconazole trough levels in relation to hepatic function: how to adjust the dosage? Br J Clin Pharm 2009;67:262-3.
14. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997;24:235-47.
15. Poirier JM, Cheymol G. Optimization of itraconazole therapy using target drug concentrations. Clin Pharm 1998;35:461-73.
16. Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IG. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 1999;42:591-600.
17. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60.
18. Ying C, Zhang ZJ. Quantification of voriconazole in human plasma by high-performance liquid chromatographyelectrospray ionization mass spectrometry: application to a bioequivalence study. Arzneimittel-Forschung 2011;61:132-9.
19. Vogeser M, Schiel X, Spohrer U. Quantification of voriconazole in plasma by liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med 2005;43:730-4.
20. Xiong X, Duan JL, Zhai SD, Wang LJ, Lan X. Fast and reliable determination of voriconazole in human plasma by LC-APCI-MS/MS. Biosci Biotechnol Biochem 2010;74:2151-3.
21. Koks CH, Sparidans RW, Lucassen G, Crommentuyn KM, Beijnen JH. Selective high-performance liquid chromatographic assay for itraconazole and hydroxyitraconazole in plasma from human immunodeficiency virus-infected patients. J Chromatogr B 2002;767:103-10.
22. Rhim SY, Park JH, Park YS, Kim DS, Lee MH, Shaw LM, et al. A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. Pharmazie 2009;64:71-5.
23. Bharathi DV, Hotha KK, Sagar PV, Kumar SS, Reddy PR, Naidu A, et al. Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of itraconazole and hydroxyitraconazole in human plasma: application to a bioequivalence study. J Chromatogr B 2008;868:70-6.
24. Kousoulos C, Tsatsou G, Apostolou C, Dotsikas Y, Loukas YL. Development of a high-throughput method for the determination of itraconazole and its hydroxy metabolite in human plasma, employing automated liquid-liquid extraction based on 96-well format plates and LC/MS/MS. Anal Bioanal Chem 2006;384:199-07.
25. Jia JY, Lu C, Liu GY, Zhang MQ, Liu YM, Wang W, et al. Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by liquid chromatography-isotope dilution tandem mass spectrometry method. Biomed Chromatogr 2010;24:648-54.
26. Alffenaar JW, Wessels AM, van Hateren K, Greijdanus B, Kosterink JG, Uges DR. Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. J Chromatogr B Technol Biomed Life Sci 2010;878:39-44.
27. Baietto L, D'Avolio A, Ventimiglia G, De Rosa FG, Siccardi M, Simiele M, et al. Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. Antimicrob Agents Chemother 2010;54:3408-13.
28. Beste KY, Burkhardt O, Kaever V. Rapid HPLP-MS/MS method for simultaneous quantitation of four routinely administered triazole antifungals in human plasma. Clin Chim Acta 2012;413:240-5.
29. Verdier MC, Bentué-Ferrer D, Tribut O, Bellissant E. Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma. Clin Chem Lab Med 2010;48:1515-22.
30. Decosterd LA, Rochat B, Pesse B, Mercier T, Tissot F, et al. Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-Oxide, anidulafungin, and caspofungin. Antimicrob Agents Chemother 2010;54:5303-15.
31. Souverain S, Rudaz S, Vouthey JL. Matrix effect in LC-ESI-MS and LC-APCI-MS with off-line and on-line extraction procedures. J Chromatogr A 2004;1058:61-6.
32. Dams R, Huestis MA, Lambert WE, Murphy CM. Urine drug testing for opioids, cocaine, and metabolites by direct injection liquid chromatography/tandem mass spectrometry. J Am Soc Mass Spectrom 2003;14:1290-4.
33. Schuhmacher J, Zimmer D, Tesche F, Pickard V. Matrix effects during analysis of plasma samples by electrospray and atmospheric pressure chemical ionization mass spectrometry: practical approaches to their elimination. Rapid Commun Mass Spectrom 2003;17:1950-7.
34. Guidance for Industry: Bioanalytical Method Validation [2001] US Department of Health and Human Services US Department of Health and Human Services, Food and Drug Administration. Available from: http://www.fda.gov/cder/ guidance/index.htm. Accessed on 25 June 2011.